As you may recall if you read Fight Aging!, TheraVitae is attempting to commercialize offshore stem cell treatments for US residents; the degree to which they succeed will certainly be widely noted in the venture investment community. This release at Genetic Engineering News gives some indications as to how the effort is going: TheraVitae has "presented interim clinical data showing significant improvement in patients suffering from severe angina pectoris six months after they received the company's autologous adult stem cell therapy. ... The benefit to patients' quality of life is a particularly positive aspect of the results we have seen and has convinced us to start treating patients with no other therapeutic options outside of the clinical trial. Thus, several dozen patients with severe angina and/or heart failure have already been treated off trial in Thailand."